A Novel Antibiotic Adjuvant Entity Against Multi-Drug Resistance

Main Article Content

Maha Bahjat Al Madani , Fatimah Khalifah Mohammad Al Sulaiman

Abstract

In critical care units, multidrug-resistant gram-positive bacteria are the cause of a number of diseases that range in severity from serious to deadly (ICUs). It has been reported that Staphylococcus aureus and its numerous multidrug-resistant forms, such as heterogeneous glycopeptide-intermediate S. aureus (hGISA) and Methicillin-resistant S. aureus (MRSA), are the most virulent pathogens in humans, and there are few or no treatment options available for them. We evaluated the in vitro interaction of ceftriaxone plus sulbactam with disodium edetate, a Non Antibiotic Adjuvant (NAA), against a selection of clinical isolates, and we also did in vitro susceptibility investigations. Our findings may be found in this work.

Article Details

Section
Articles